Michael W Konstan

Summary

Affiliation: University Hospitals Case Medical Center
Country: USA

Publications

  1. doi request reprint A randomized double blind, placebo controlled phase 2 trial of BIIL 284 BS (an LTB4 receptor antagonist) for the treatment of lung disease in children and adults with cystic fibrosis
    M W Konstan
    Rainbow Babies and Children s Hospital, Cleveland, OH, USA Case Western Reserve University, Cleveland, OH, USA Electronic address
    J Cyst Fibros 13:148-55. 2014
  2. doi request reprint Tobramycin inhalation powder for P. aeruginosa infection in cystic fibrosis: The EVOLVE trial
    Michael W Konstan
    Rainbow Babies and Children s Hospital, and Case Western Reserve University School of Medicine, Cleveland, Ohio
    Pediatr Pulmonol 46:230-8. 2011
  3. doi request reprint Risk factors for rate of decline in FEV1 in adults with cystic fibrosis
    Michael W Konstan
    Case Western Reserve University School of Medicine and Rainbow Babies and Children s Hospital, Cleveland, OH 44106, USA
    J Cyst Fibros 11:405-11. 2012
  4. doi request reprint Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial
    Michael W Konstan
    Rainbow Babies and Children s Hospital, Case Western Reserve University School of Medicine, Cleveland, OH, USA
    J Cyst Fibros 10:54-61. 2011
  5. doi request reprint Pulmonary outcome prediction (POP) tools for cystic fibrosis patients
    Donald R VanDevanter
    Case Western Reserve University School of Medicine, Cleveland, Ohio, USA
    Pediatr Pulmonol 45:1156-66. 2010
  6. doi request reprint Trends in the use of routine therapies in cystic fibrosis: 1995-2005
    Michael W Konstan
    Case Western Reserve University School of Medicine, Cleveland, Ohio, USA
    Pediatr Pulmonol 45:1167-72. 2010
  7. ncbi request reprint Risk factors for rate of decline in forced expiratory volume in one second in children and adolescents with cystic fibrosis
    Michael W Konstan
    Department of Pediatrics, Rainbow Babies and Children s Hospital and Case Western Reserve University School of Medicine, Cleveland, Ohio 44106, USA
    J Pediatr 151:134-9, 139.e1. 2007
  8. ncbi request reprint Inflammation and anti-inflammatory therapies for cystic fibrosis
    James F Chmiel
    Division of Pediatric Pulmonology, Department of Pediatrics, Case Western Reserve University School of Medicine, 11100 Euclid Avenue, Cleveland, OH 44106, USA
    Clin Chest Med 28:331-46. 2007
  9. ncbi request reprint The efficacy and safety of meropenem and tobramycin vs ceftazidime and tobramycin in the treatment of acute pulmonary exacerbations in patients with cystic fibrosis
    Jeffrey L Blumer
    Rainbow Babies and Children s Hospital, Case Western Reserve University School of Medicine, Cleveland, OH, USA
    Chest 128:2336-46. 2005
  10. doi request reprint Clinical use of dornase alpha is associated with a slower rate of FEV1 decline in cystic fibrosis
    Michael W Konstan
    Case Western Reserve University School of Medicine, Cleveland, Ohio, USA
    Pediatr Pulmonol 46:545-53. 2011

Detail Information

Publications37

  1. doi request reprint A randomized double blind, placebo controlled phase 2 trial of BIIL 284 BS (an LTB4 receptor antagonist) for the treatment of lung disease in children and adults with cystic fibrosis
    M W Konstan
    Rainbow Babies and Children s Hospital, Cleveland, OH, USA Case Western Reserve University, Cleveland, OH, USA Electronic address
    J Cyst Fibros 13:148-55. 2014
    ..We report the results of a randomized, double-blind, placebo-controlled study of the efficacy and safety of the leukotriene B4 (LTB4)-receptor antagonist BIIL 284 BS in CF patients...
  2. doi request reprint Tobramycin inhalation powder for P. aeruginosa infection in cystic fibrosis: The EVOLVE trial
    Michael W Konstan
    Rainbow Babies and Children s Hospital, and Case Western Reserve University School of Medicine, Cleveland, Ohio
    Pediatr Pulmonol 46:230-8. 2011
    ..Pediatr Pulmonol. 2011; 46:230-238. © 2011 Wiley-Liss, Inc. ..
  3. doi request reprint Risk factors for rate of decline in FEV1 in adults with cystic fibrosis
    Michael W Konstan
    Case Western Reserve University School of Medicine and Rainbow Babies and Children s Hospital, Cleveland, OH 44106, USA
    J Cyst Fibros 11:405-11. 2012
    ..Previously we assessed risk factors for FEV(1) decline in children and adolescents using the Epidemiologic Study of Cystic Fibrosis (J Pediatr 2007;151:134-139); the current study assessed risk factors in adults...
  4. doi request reprint Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial
    Michael W Konstan
    Rainbow Babies and Children s Hospital, Case Western Reserve University School of Medicine, Cleveland, OH, USA
    J Cyst Fibros 10:54-61. 2011
    ....
  5. doi request reprint Pulmonary outcome prediction (POP) tools for cystic fibrosis patients
    Donald R VanDevanter
    Case Western Reserve University School of Medicine, Cleveland, Ohio, USA
    Pediatr Pulmonol 45:1156-66. 2010
    ..Loss of lung function in patients with cystic fibrosis (CF) is associated with increased mortality and varies between individuals and over time. Predicting this decline could improve patient management...
  6. doi request reprint Trends in the use of routine therapies in cystic fibrosis: 1995-2005
    Michael W Konstan
    Case Western Reserve University School of Medicine, Cleveland, Ohio, USA
    Pediatr Pulmonol 45:1167-72. 2010
    ..Notable increases in use of therapies, particularly of inhaled therapies, suggest that overall patient treatment burden must have risen correspondingly...
  7. ncbi request reprint Risk factors for rate of decline in forced expiratory volume in one second in children and adolescents with cystic fibrosis
    Michael W Konstan
    Department of Pediatrics, Rainbow Babies and Children s Hospital and Case Western Reserve University School of Medicine, Cleveland, Ohio 44106, USA
    J Pediatr 151:134-9, 139.e1. 2007
    ..To characterize the rate of decline of forced expiratory volume in 1 second (FEV(1)) in children and adolescents with cystic fibrosis and to identify and compare risk factors associated with FEV(1) decline...
  8. ncbi request reprint Inflammation and anti-inflammatory therapies for cystic fibrosis
    James F Chmiel
    Division of Pediatric Pulmonology, Department of Pediatrics, Case Western Reserve University School of Medicine, 11100 Euclid Avenue, Cleveland, OH 44106, USA
    Clin Chest Med 28:331-46. 2007
    ..This article reviews the current state of the art of anti-inflammatory therapy in cystic fibrosis and introduces clinical trials that are underway...
  9. ncbi request reprint The efficacy and safety of meropenem and tobramycin vs ceftazidime and tobramycin in the treatment of acute pulmonary exacerbations in patients with cystic fibrosis
    Jeffrey L Blumer
    Rainbow Babies and Children s Hospital, Case Western Reserve University School of Medicine, Cleveland, OH, USA
    Chest 128:2336-46. 2005
    ....
  10. doi request reprint Clinical use of dornase alpha is associated with a slower rate of FEV1 decline in cystic fibrosis
    Michael W Konstan
    Case Western Reserve University School of Medicine, Cleveland, Ohio, USA
    Pediatr Pulmonol 46:545-53. 2011
    ..We assessed the relationship of dornase alpha use and FEV(1) decline using the Epidemiologic Study of Cystic Fibrosis (ESCF)...
  11. ncbi request reprint Genetic modifiers of lung disease in cystic fibrosis
    Mitchell L Drumm
    Department of Pediatrics, Case Western Reserve University, Cleveland, USA
    N Engl J Med 353:1443-53. 2005
    ..Polymorphisms in genes other than the cystic fibrosis transmembrane conductance regulator (CFTR) gene may modify the severity of pulmonary disease in patients with cystic fibrosis...
  12. ncbi request reprint Compacted DNA nanoparticles administered to the nasal mucosa of cystic fibrosis subjects are safe and demonstrate partial to complete cystic fibrosis transmembrane regulator reconstitution
    Michael W Konstan
    Department of Pediatrics, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA
    Hum Gene Ther 15:1255-69. 2004
    ..In conclusion, compacted DNA nanoparticles can be safely administered to the nares of CF subjects, with evidence of vector gene transfer and partial NPD correction...
  13. pmc Classifying severity of cystic fibrosis lung disease using longitudinal pulmonary function data
    Mark D Schluchter
    Department of Pediatrics, Case Western Reserve University, Cleveland, OH 44106 4945, USA
    Am J Respir Crit Care Med 174:780-6. 2006
    ..One type of genetic association study design compares polymorphisms in patients at extremes of phenotype, requiring accurate classification of pulmonary disease at varying ages...
  14. ncbi request reprint Prolonged inflammatory response to acute Pseudomonas challenge in interleukin-10 knockout mice
    James F Chmiel
    Department of Pediatrics, Rainbow Babies and Children s Hospital, Case Western Reserve University School of Medicine, Cleveland, Ohio 44106, USA
    Am J Respir Crit Care Med 165:1176-81. 2002
    ..These data suggest that IL-10 deficiency contributes to prolonged inflammatory responses early in CF, when infection may be transient...
  15. pmc Assessing time to pulmonary function benefit following antibiotic treatment of acute cystic fibrosis exacerbations
    Donald R VanDevanter
    Case Western Reserve University School of Medicine, Cleveland, OH, USA
    Respir Res 11:137. 2010
    ..However, no prospective studies have identified an optimal antibiotic treatment duration and this lack of objective data has been identified as an area of concern and interest...
  16. pmc Clinical use of Ibuprofen is associated with slower FEV1 decline in children with cystic fibrosis
    Michael W Konstan
    Rainbow Babies and Children s Hospital, 11100 Euclid Avenue, Cleveland, OH 44106, USA
    Am J Respir Crit Care Med 176:1084-9. 2007
    ..High-dose ibuprofen in a 4-year controlled trial slowed FEV(1) decline in young subjects with cystic fibrosis, but the effectiveness of ibuprofen has not been assessed in a large group of patients treated clinically with this therapy...
  17. ncbi request reprint Anti-inflammatory medications for cystic fibrosis lung disease: selecting the most appropriate agent
    James F Chmiel
    Department of Pediatrics, Case Western Reserve University School of Medicine, Rainbow Babies and Children s Hospital, Cleveland, OH 44106, USA
    Treat Respir Med 4:255-73. 2005
    ..Until those therapies aimed at repairing the basic defect are realized, limiting the effects of the inflammatory process will be important in slowing the decline in lung function and thus prolonging survival in patients with CF...
  18. doi request reprint Effect of dornase alfa on inflammation and lung function: potential role in the early treatment of cystic fibrosis
    Michael W Konstan
    Case Western Reserve University School of Medicine and Rainbow Babies and Children s Hospital, 11100 Euclid Avenue, Cleveland, OH 44106, USA
    J Cyst Fibros 11:78-83. 2012
    ..These encouraging results, possibly linked to indirect effects on inflammation, suggest a greater role for dornase alfa therapy in the early treatment of CF, where it may help preserve lung function and potentially extend survival...
  19. doi request reprint Characterizing aggressiveness and predicting future progression of CF lung disease
    Michael W Konstan
    Department of Pediatrics, Rainbow Babies and Children s Hospital, Case Western Reserve University School of Medicine, Cleveland, Ohio 44106, USA
    J Cyst Fibros 8:S15-9. 2009
    ....
  20. doi request reprint Anti-inflammatory therapies for cystic fibrosis-related lung disease
    David P Nichols
    Department of Pediatrics, Case Western Reserve University School of Medicine, Rainbow Babies and Children s Hospital, Cleveland, OH, USA
    Clin Rev Allergy Immunol 35:135-53. 2008
    ..Available data from studies commenced over the last two decades, which have generated both encouraging and disappointing results, are reviewed below...
  21. ncbi request reprint The role of inflammation in the pathophysiology of CF lung disease
    James F Chmiel
    Department of Pediatrics, Case Western Reserve University School of Medicine, Division of Pediatric Pulmonology, Rainbow Babies and Children s Hospital, Cleveland, OH, USA
    Clin Rev Allergy Immunol 23:5-27. 2002
    ....
  22. doi request reprint Ibuprofen therapy for cystic fibrosis lung disease: revisited
    Michael W Konstan
    Department of Pediatrics, Case Western Reserve University School of Medicine and Rainbow Babies and Children s Hospital, Cleveland, Ohio 44106, USA
    Curr Opin Pulm Med 14:567-73. 2008
    ..Additional clinical studies were advocated to better assess the risk-benefit profile. The results of several studies have been published within the last couple of years...
  23. doi request reprint Changing thresholds and incidence of antibiotic treatment of cystic fibrosis pulmonary exacerbations, 1995-2005
    Donald R VanDevanter
    Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA
    J Cyst Fibros 12:332-7. 2013
    ..Increased chronic therapy use and improved cystic fibrosis (CF) patient health should be accompanied by reduced pulmonary exacerbation-associated antibiotic treatment incidence...
  24. ncbi request reprint Growth and nutritional indexes in early life predict pulmonary function in cystic fibrosis
    Michael W Konstan
    Department of Pediatrics, Rainbow Babies and Children s Hospital and Case Western Reserve University School of Medicine, Cleveland, Ohio, USA
    J Pediatr 142:624-30. 2003
    ..To determine the relation of growth and nutritional status to pulmonary function in young children with cystic fibrosis (CF)...
  25. pmc The role of inhaled corticosteroids in the management of cystic fibrosis
    Kristie R Ross
    Department of Pediatrics, Division of Pulmonology, Case Western Reserve University School of Medicine, Rainbow Babies and Children s Hospital, Cleveland, Ohio, USA
    Paediatr Drugs 11:101-13. 2009
    ..This review provides an overview of the inflammatory response in CF, the mechanisms of action of corticosteroids, the safety of ICS, and the literature relevant to the use of ICS in CF...
  26. ncbi request reprint Effect of ibuprofen on neutrophil migration in vivo in cystic fibrosis and healthy subjects
    Michael W Konstan
    Department of Pediatrics, Case Western Reserve University School of Medicine, Rainbow Babies and Children s Hospital, Cleveland, OH 44106, USA
    J Pharmacol Exp Ther 306:1086-91. 2003
    ....
  27. ncbi request reprint Relation of sweat chloride concentration to severity of lung disease in cystic fibrosis
    Pamela B Davis
    Department of Pediatrics, Case Western Reserve University School of Medicine, Cleveland, Ohio 44106, USA
    Pediatr Pulmonol 38:204-9. 2004
    ..These data suggest that, by itself, sweat chloride concentration does not necessarily predict a milder pulmonary course in patients with cystic fibrosis...
  28. doi request reprint Association between respiratory tract methicillin-resistant Staphylococcus aureus and survival in cystic fibrosis
    Elliott C Dasenbrook
    Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine, Case Western Reserve University School of Medicine and University Hospitals Case Medical Center, Cleveland, Ohio 44106 5067, USA
    JAMA 303:2386-92. 2010
    ..Because the time between infection with bacteria in CF and death can be decades, observational studies with long periods of follow-up are well suited to address the current gap in knowledge...
  29. ncbi request reprint Beta 2 adrenergic receptor polymorphisms in cystic fibrosis
    Meeghan A Hart
    Department of Pediatrics, Case Western Reserve University and Rainbow Babies and Children s Hospital, Cleveland, Ohio 44106, USA
    Pediatr Pulmonol 39:544-50. 2005
    ..These data are consistent with variants of the ADRB2 gene having different responses to bronchodilator, but the long-term effects, if any, are not apparent over a 5-year period...
  30. ncbi request reprint Pharmacological approaches for the discovery and development of new anti-inflammatory agents for the treatment of cystic fibrosis
    Michael W Konstan
    Department of Pediatrics, Case Western Reserve University School of Medicine and Rainbow Babies and Children s Hospital, 11100 Euclid Avenue, Cleveland, OH 44106, USA
    Adv Drug Deliv Rev 54:1409-23. 2002
    ....
  31. ncbi request reprint Non-viral gene transfer therapy for cystic fibrosis
    Assem G Ziady
    Department of Pediatrics, Case Western Reserve University, 11100 Euclid Avenue, Cleveland, OH 44106, USA
    Expert Opin Biol Ther 3:449-58. 2003
    ..modifying the plasmid DNA to reduce inflammatory CpG sequences and enhance intensity, duration and tissue specificity of expression, and iv). modification of the complexes to improve nuclear access...
  32. pmc Antibiotic and anti-inflammatory therapies for cystic fibrosis
    James F Chmiel
    Department of Pediatrics, Case Western Reserve University School of Medicine, Rainbow Babies and Children s Hospital, Cleveland, Ohio 44106
    Cold Spring Harb Perspect Med 3:a009779. 2013
    ..It is likely that antibiotics and anti-inflammatory drugs will remain an important part of the maintenance regimen for CF in the foreseeable future. Current and future antibiotic and anti-inflammatory therapies for CF are reviewed. ..
  33. pmc Normalized T1 magnetic resonance imaging for assessment of regional lung function in adult cystic fibrosis patients--a cross-sectional study
    Elliott C Dasenbrook
    Department of Pediatrics, Case Western Reserve University School of Medicine, University Hospitals Case Medical Center and Rainbow Babies and Children s Hospital, Cleveland, Ohio, United States of America Department of Medicine, Case Western Reserve University School of Medicine, University Hospitals Case Medical Center and Rainbow Babies and Children s Hospital, Cleveland, Ohio, United States of America
    PLoS ONE 8:e73286. 2013
    ..We developed a rapid normalized T1 MRI technique to detect regional lung disease in early-stage CF patients...
  34. pmc Emergence of linezolid-resistant Staphylococcus aureus after prolonged treatment of cystic fibrosis patients in Cleveland, Ohio
    Andrea Endimiani
    Department of Medicine, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA
    Antimicrob Agents Chemother 55:1684-92. 2011
    ..Emergence of LRSA is a serious concern for CF patients who undergo prolonged courses of LZD therapy...
  35. ncbi request reprint Jointly modelling the relationship between survival and pulmonary function in cystic fibrosis patients
    Mark D Schluchter
    Department of Pediatrics, Rainbow Babies and Children s Hospital, Case Western Reserve University, Cleveland, OH, USA
    Stat Med 21:1271-87. 2002
    ..s.a...
  36. ncbi request reprint Murine models of CF airway infection and inflammation
    James F Chmiel
    Department of Pediatrics, Rainbow Babies and Children s Hospital, Case Western Reserve University School of Medicine, Cleveland, OH, USA
    Methods Mol Med 70:495-515. 2002
  37. ncbi request reprint Inflammatory mediators in CF patients
    Jay B Hilliard
    Department of Pediatrics, Rainbow Babies and Children s Hospital, Case Western Reserve University School of Medicine, Cleveland, OH, USA
    Methods Mol Med 70:409-31. 2002